New Delhi, Nov 05 (ANI/Business Wire India): Deloitte India announced today the commencement of an Indian-Belgian Bio-Pharma forum across Delhi and Mumbai starting today.
H.M. Albert II, King of Belgium and H.M Paola, Queen of Belgium who are visiting India are attending this forum on November 6 in Mumbai.
The forum is hosted to provide bilateral contacts between India and Belgium to promote Belgian biopharmaceutical companies. The seminar will showcase biopharmaceutical companies from Belgium, presenting their expertise to position Belgium as a land of investment for the biopharmaceutical industry.
The seminar in New Delhi will focus on "Belgium, a center of world-class Neurology Rand D". It will showcase eminent speakers and will be followed by a session on partnerships between industry and academia in India and Belgium. The forum will be marked by the presence of H.M. Paola, Queen of Belgium.
The seminar in Mumbai will focus on "Belgium and India, two complementary and growing biopharma clusters".
It will be attended by H.M. King Albert II and Karel De Gucht, Minister of Foreign Affairs of Belgium. In the forum Deloitte India will showcase a presentation on "New Developments of the Indian Business Environment" which will highlight the characteristics of the Indian economy, current global scenario, its impact on India and the effect on critical sectors.
Talking on Deloitte India's participation in the seminar Prashant Deshpande, Senior Director Tax Services said "We are glad to participate in the Indian-Belgium Business Forum as it offers business opportunities between the two countries. It will boost economic, trade and investment cooperation, enhancing the mutual understanding of the business community of both the countries."
Belgium has become a hub for the biopharma sector. It has over 200 small and medium-sized enterprises in the life sciences sector, specializing in fundamental and clinical research. The country also heads the world in terms of the number of drugs being developed per capita, in all categories.
In absolute figures, Belgium is also the world's leading export country for drugs and the seventh largest investor in R and D. The combination of several focused tax measures makes Belgium one of the most attractive investment locations for biopharmaceutical R and D and manufacturing in the European Union.
With the highest concentration of life-science employees in the world the country has become the birthplace of several world research and development centres for the biopharmaceuticals industry. The country provides a large, dynamic and stimulating environment for biopharma companies for investment.
Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, and its network of member firms, each of which is a legally separate and independent entity.
Deloitte provides professional services to public and private clients spanning multiple industries. With a globally connected network of member firms in 140 countries, Deloitte brings world-class capabilities and deep local expertise to help clients succeed wherever they operate. Deloitte's 165,000 professionals are committed to becoming the standard of excellence.